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ABSTRACT 
CONTEXT 
Nowadays, the entire manufacturing process is based on the current GMPs, which emphasize the 
reproducibility of the process, and companies have a lot of recorded data about their processes.  
OBJECTIVE 
The establishment of the design space (DS) from retrospective data for a wet compression process.  
MATERIALS AND METHODS 
A design of experiments (DoE) with historical data from four years of industrial production has been 
carried out  using as experimental factors the results of the previous risk analysis and eight key 
parameters (quality specifications) that encompassed process and quality control data.  
RESULTS 
Software Statgraphics 5.0 was applied and data were processed to obtain 8 design spaces as well as 
their safe and working ranges. 
DISCUSSION AND CONCLUSION 
Experience shows that it is possible to determine design spaces retrospectively, being the greatest 
difficulty the handling and processing of high amounts of data; however, the practicality of this study is 
very interesting as it let have the design space with minimal investment in experiments since actual 
production batch data are processed statistically. 
 
1. INTRODUCTION 
Nowadays, the entire manufacturing process is based on the current GMPs, which emphasize the 
reproducibility of the process. Once validated, the process is "frozen" and activities are reduced to the 
control of the parameters that may influence the process, resulting in a gathered process data which is 
never used subsequently. Product release depends on the analytical results of quality control, which 
show that the product meets previously approved regulatory specifications. 
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Since the appearance in 2003 of the so-called GMPs for the 21st century (US FDA, 2003) by the FDA, it 
can be said that the vision of both the administration and the industry has expanded up to a more 
practical pharmaceutical and industrial quality approach based on data which ensures, at least, the 
prior same level of quality based on validation and process controls. 
 
The concepts introduced by the International Conference of Harmonization (ICH) in its guidelines Q8: 
Pharmaceutical Development (ICH Q8, 2005), Q9: Quality Risk Management (ICH Q9, 2005) or Q10: 
Pharmaceutical Quality System (ICH Q10, 2008), or ICH guideline Q11 on the Development and 
Manufacture of Drug Substances (ICH Q11, 2012) (chemical entities and biotechnological/biological 
entities), refer to a new understanding of pharmaceutical quality compared to pharmaceutical 
development and industrial production. 
 
The concept of "design space" has been proposed in the ICH Q8 guideline and it has been defined as 
"the multidimensional combination and interaction of input variables (e.g., material attributes) and 
process parameters that have been demonstrated to provide assurance of quality". (ICH Q8, 2005) 
Process characterization studies are performed primarily at laboratory scale with the purpose of 
defining the "design space" within which the process can operate and still perform in an acceptable 
fashion with respect to product quality and process consistency. In this sense, decision-taking based on 
deep scientific knowledge of the product and its process is sought; removing the causes of major 
deviations and forcing the incorporation of the process into a cycle of continuous improvement as a way 
of minimizing the risk of variability of product quality and as a contribution to the continuous 
improvement of the process. 
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This approach pursues product Quality by Design versus the current concept of complying uniquely 
with the registered specifications (Quality by Evidence). The objective is to build quality in the product 
and not to rely on end product testing. A highly detailed instance is the example of "QbD IR tablets" 
published in 2011 for generic drugs that points which would be the best approach during the 
development of the pharmaceutical dosage form (US FDA, 2012). According to ICH recommendations, 
all critical sources of variability must identified and explained, the intervals within which you can work 
freely (Design Space or DS) must be set with the certainty of obtaining an end product of the desired 
quality. QbD requires statistical methods to be used in pharmaceutical formulation and process 
development. Tools such as FMEA, scale-down modeling, and DOE have been shown to be effective 
for performing an efficient examination of process robustness (Charoo and Ali, 2012). For quality and 
productivity improvement, the most cost beneficial of these methods is statistical Design of Experiments 
(DoE). A trial-and-error search for the few vital factors that most affect quality is costly and time-
consuming, as many authors who have worked in this field (Baum, 2007; Beneyto, 2007; Raju, 2003; 
Rudd, 2002) have affirmed. 
 
Although the ICH Q8 refers primarily to the pharmaceutical development stage, our hypothesis is that 
the establishment of the design space (DS) may also be considered in existing products retrospectively. 
In this case the DS is established as a work frame based on process and product historical data, 
confirming the previously conducted risk analysis according to the premises of the guideline guidelines 
of the ICH Q9. The ICH document of questions and answers about QbD (ICH working group, 2010) 
already considered this possible application; the ICH response leaves the door open to possibilities “for 
manufacturing operations run under narrow operational ranges in fixed equipment, an expanded region 
range of operation and an understanding of multi-parameter interactions may not be achievable from 
existing manufacturing data alone and additional studies may provide the information to develop a 
design space. Sufficient knowledge should be demonstrated and the design space should be supported 
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experimentally to investigate interactions and establish parameter/attribute ranges” (ICH working group, 
2010). A number of Numerous papers have been published for the development of the design space 
from the earliest stages of development for both drug and biopharmaceutical products (Adam et al., 
2011; Baldinger et al., 2012; Charoo et al., 2012; Cook et al., 2007; García-Muñoz et al., 2010; Harms 
et al., 2008; Huang, 2011; Huang et al., 2009; Johnson et al., 2007; Kirdar et al., 2008; Kirdar et al., 
2007; Konold et al., 2009; Kozlowski and Swann, 2006; Lebrun et al., 2012; Peterson, 2008; Rathore 
and Winkle, 2009); however, QbD implementation for new products is well documented but it is not for 
existing products. The key drivers for the Implementation of QbD into existing products are to reduce 
variability in the product quality, improve yield, reduce cycle time, solve manufacturing issues, reduce 
quality costs and the introduction of real time release testing for manufacturing processes (Garcia et al., 
2008; Gautam et al., 2012; Johnson et al., 2007; Lourenço et al., 2012; Potter, 2009; Yu, 2008). 
 
Despite the future possibilities (process characterization studies can serve as a foundation for a 
successful process validation, regulatory filing/approval, and subsequent manufacturing during the 
product lifecycle), few studies have been found (Gautam et al., 2012; Potter, 2009; Rathore and Winkle, 
2009; Rathore et al., 2009) published on the subject that demonstrate this applicability. However, 
Potter’s work is not fully developed in the article and does not provide any graphics, and Rathore’s 
actually applies the Six Sigma concepts and in the second example, it shows through it does show via 
small scale experiments that all lots meet the design space proposed by the DoE carried out. Gautam's 
case is also exemplary, concerning a chemical process which managed to reduce the variability of the 
dimer impurity and reduce costs, properly implementing QbD to an existing chemical process. 
 
This paper presents a stepwise approach in order to define the design space process for an existing 
product, which has been manufactured industrial-scale during four years. So, it provides a perspective 
of QbD application for tablet manufacturing using an example from a previous manufacturing process.  
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The objective of this work is to identify the critical points for inclusion in the design space proposed for 
the process, which will be established retrospectively. This goal will be achieved through the study and 
knowledge of the process and thanks to the incorporation of risk analysis and statistical analysis tools. 
The method to establish a retrospective design space involves the management of the retrospective 
data of 23 industrial batches, both in terms of process parameters and finished product specifications. 
As it is an initial approximation, it has been carried out with the first part of a coated tablet production 
process, that is, the compression process but not the coating process design space was carried out. 
 
2. MATERIALS AND METHODS 
The product selected for the study belongs to the portfolio of a multinational pharmaceutical company 
and it is already marketed. From the pharmaceutical technology standpoint, the product can be 
characterized as a solid dosage form, obtained by wet granulation, fluid bed drying and subsequent 
compression. It then undergoes a stage of tablet coating and screen-printing, as a preliminary stage to 
packaging. 
 
The proposed study is retrospective, based on documentary records of batches produced in the same 
site for the first four years of production (2003-2006). In addition, the equipment and facilities used are 
the same, as it is the equipment used for analysis in quality control laboratory. During the study period, 
no significant change controls were registered for the established manufacturing process. Therefore, 
the report will also be valid to obtain the product PQR. 
The overall approach toward process characterization involved four key steps:  
• First, risk analysis via FMEA (Failure Mode and Effects Analysis) was performed to identify 
parameters for process characterization.  
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• Second, data from 23 batches manufactured for four years were collected, as much analytical 
results from API and finished product as process control (analytical results and manufacturing 
parameters). 
• Third, statistical studies were designed using DoE in order to define the design space and to 
analyze the results for deciding on the criticality of the parameters as well as on establishing 
design space. 
• Fourth, the design space for the compression process was established. These steps will be 
discussed in more detail in the following sections. 
 
3. RESULTS 
Below the results of the execution of the established stages for the study of the manufacturing process 
are described. 
Following the guidelines set out in ICH Q9, a series of stages needed for a proper study of the process 
are executed. In the VII stage, the FMEA (Failure Mode and Effects Analysis) tool has been selected as 
it is the most widespread in the European Pharmaceutical Industry. The stages are: 
3.1 SCOPE OF ANALYSIS DEFINITION DEFINE THE SCOPE OF ANALYSIS 
3.2 ESTABLISH THE SOURCES OF INFORMATION ESTABLISHMENT 
3.3 PROCESS STEPS DEFINITION DEFINE PROCESS STEPS (“Process Mapping”).  
3.4 ESTABLISH THE ANALYSIS MATRICES ESTABLISHMENT (for FMEA) 
3.5 FAILURES IDENTIFICATION IDENTIFY FAILURES 
3.6 FAILURES EFFECTS IDENTIFICATION IDENTIFY THE EFECTS OF FAILURES (for product 
quality) 
3.7 RISK ASSESSMENT (using FMEA). 
3.8 SELECTION OF PRODUCT REAL DATA 
3.9 COLLECTION OF INFORMATION 
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3.10 RISK MITIGATION MEASURES IMPLEMENTATION ESTABLISH RISK MITIGATION 
MEASURES (if required) 
3.11 STATISTICAL ANALYSIS OF DATA TO ESTABLISH THE PROCESS DESIGN SPACE 
3.1 SCOPE OF ANALYSIS DEFINITION DEFINE THE SCOPE OF ANALYSIS 
The first step to define the design space for the manufacturing process was to identify CQAs (Critical 
Quality Attributes). Obvious CQAs are defined as a drug substance characteristic that has a direct or 
indirect impact on the safety and efficacy of the drug product. In this regard, the work paper of Yu (Yu, 
2008) provide us with a list of process parameters and quality attributes for the compression process 
and the work paper of Garcia (Garcia et al., 2008) offer a worked example that is similar to ours. 
According to the product quality dossier, the available quality parameters of the formula are: 
dissolution, assay on the mixture and on the tablet, and impurities in the tablet. 
The process for obtaining the finished pharmaceutical product, ready for being distributed, is divided 
into the following stages: 
o Preparation of tablets:   
1. Wet granulation 
2. Compression→Coating→ Screen-printing 
o Packaging: blister and cartoning 
The work is focused on the study of the wet granulation process and in the obtention of the final 
mixture, as these stages are considered to be critical for subsequent steps of compression and coating. 
Obtaining a good mixture and subsequent granulation is considered critical for product quality attributes 
such as content uniformity and the quantification appearance of degradation products. 
The final granulate is compressed in a Fette 3090 model machine, which has a process capacity (Cp) 
of greater than 2.5 (equivalent to ± 6σ), and so the variability it contributes to the overall process is very 
low. The tablets are coated in a Glatt coating pan; finally they are screen-printed with a small anagram 
and packaged. During the first stage of the coating process, an insulating layer is generated which 
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prevents the tablet from moisturizing during coating and therefore the impact of moisture on the final 
tablet is not considered relevant. Also, because the tablets are dried, the temperature rise that occurs 
during coating it is not considered a major impact. Hence, it has been considered that all modifications 
of impurity values are associated to the stages of granulation and fluid bed drying. 
3.2 ESTABLISH THE SOURCES OF INFORMATION ESTABLISHMENT 
The information to be used in this study comes from: 
 Manufacturing process data: Batch Record with the values of the process parameters recorded 
during manufacture, either in line or through automated control systems. 
 Data from laboratory quality control certificates: active substance, intermediate and finished 
products.  
 All data on product pharmaceutical development are also are available for consultation. 
3.3 PROCESS STEPS DEFINITION DEFINE PROCESS STEPS (“Process Mapping”) 
The process map provides a visual understanding of the process to study, explaining and unfold the 
complex processes into simpler stages. In our case, the process map would be limited to the 
highlighted area in Figure 1. 
3.4 ESTABLISH THE ANALYSIS MATRICES ESTABLISHMENT 
The first thing is to define the scales to be used in the FMEA during the risk assessment stage. For this, 
the correlation between the values used in rating scales and descriptions of their meanings were 
determined. Tables 1A and 1B specify the ones chosen for the study. 
Then all possible combinations within the values of severity, probability and detection (from equation 1) 
are developed, which can be used to establish all possible Risk Priority Numbers (RPN) and thus 
establish a number of courses of action based on the risk posed to product quality; table 2 shows the 
ones selected for the study. 
DETECTIONYPROBABILITSEVERITYRPN **=                  Eq (1) 
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3.5 FAILURES IDENTIFICATION IDENTIFY FAILURES & 3.6 FAILURES EFFECTS IDENTIFICATION 
IDENTIFY THE EFECTS OF FAILURES & 3.7 RISK ASSESSMENT. 
Once the evaluation matrices have been drawn up, we proceed to develop the FMEA work method. 
The first step is to establish all possible failure modes for each of the steps described in the "process 
mapping". Then proceed to describe the effects that can be produced by these failures on product 
quality. In Figure 2 is represented a “qualitative” risk analysis for our compression process, as a 
Qualitative Risk Analysis (multivariable causes and effects relationship) for process and API. Finally, 
failure assessment is carried out following the tables drawn up in point IV. 
Having completed By having all these tasks completed, a table is was drawn up containing all the 
information issued on generated. One way of displaying this data is the one presented in Table 3 and in 
the Pareto chart (Figure 3). 
This Pareto chart shows the eight factors [Binding liquid quantity (granulation), Drying time (fluid bed), 
Power consumption on endpoint kneading (granulation), Moisture at the end of drying (fluid bed), 
Moisture at the end of cooling (fluid bed), Particle size (API), Mean Particle size (Excipients), Impurities 
content (API)],  that produce most risk to the process and which should  be studied to determine 
whether their influence in the process is statistically significant or not.  
 
3.8 SELECTION OF PRODUCT REAL DATA & 3.9 COLLECTION OF INFORMATION 
According to estimated failure modes, and to corroborate the performed approach to the significance of 
each one, data from real industrial batches are were reviewed. Data were collected from 23 batches 
manufactured over 4 years, as much analytical results from API and finished product as process control 
(analytical results and manufacturing parameters). 
Quality parameters are were reviewed in the batch documentation to obtain information about possible 
failures and their effects; this is shown in detail in Table 4.Although the percentage of impurities (A, B, 
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C, others and total) of API batches were analyzed, they could not be used as process variables 
because data were available neither for the 23 batches analyzed nor for the excipients particle size. 
 
Within these real data, the variable parameters of the process are given in bold and italics in Table 4 
(therefore they will be treated as potential factors for the experimental design) and product 
specifications. 
 
3.10 RISK MITIGATION MEASURES IMPLEMENTATION ESTABLISH RISK MITIGATION 
MEASURES 
Risk mitigation measures are not applied as it is a retrospective process. However, the process controls 
themselves are already risk mitigation actions. 
 
3.11 STATISTICAL ANALYSIS OF DATA TO ESTABLISH PROCESS DESIGN SPACE 
Statistical studies were designed using DoE in order for the data to be amenable for use in defining 
using to define the design space, the results analyzed for decisions on the criticality of the parameters 
as well as on establishing design space.  
For the construction of the design space retrospectively, we proceeded as follows: 
1. - Statgrafics 5.0, statistical software was used and real raw data of from production were used. The 
outcome of quality risk assessment has identified 7 factors as potential critical process parameters that 
may significantly affect  impact the stability of tablet dissolution. These critical factors were introduced 
in the Doe, except for the particle size of the excipients, because it could not be collected raw data was 
not available from the laboratory records) plus a further 3, firstly no identified as critical, but having the 
data we have considered interesting for inclusion in the study: water content of the API, % of API 
particles greater than 500µm and blending time. Also the critical responses (product specifications) are 
shown in Table 4. 
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For the following 9 factors, that are continuous variables, data are available: 
- Amount of binder liquid: must be added to form a mass among different excipients and active 
substance. Range between: 2.1-2.785 L. Specification: 2.1-2.8 L. 
- Consumption during kneading: marks the endpoint of blending. Range between: 6.06-
6.7 Kw. Specification: 5-7 Kw. 
- Drying time: varies from 5-15 minutes. Specification: 5-15 minutes 
- API particle size (<125 microns). Varies between 31-90 microns.  
- Retained API fraction greater than 500 microns (<1%). Range between 0-1% 
- API relative humidity. Range from 0.1 to 0.2%. Specification: ≤ 0.5% 
- End blending time: range from 1152 to 1171 seconds. Specification: 1150-1200 seconds. 
- Moisture, drying phase: % range from 0.53 to 0.9 %. Specification: ≤ 1% 
- Moisture, cooling phase: % range from 0.48 to 0.81 %. Specification: ≤ 1% 
At last 12 parameters were available as responses; in Table 5 lists all of them are listed with the 
specification and the range found in the 23 batches studied. 
2. - Once the data are entered into the program, design is analyzed and those factors that are not 
significant are removed from the model. 
In Table 6 lists , factors with a significance level of 5% have been listed, meaning that the probability 
that the effect attributed to the factor is by chance is less than 5%. The boxes marked grey correspond 
to effects with a probability greater than 5%, namely that the probability that their influence is due to 
chance is more than 5%, and so it can be assumed that there is no significant relationship between the 
factor and the response analyzed. Nevertheless, the possibility of the existence of other relationships of 
co-linearity between the factors studied has been taken into account, the existence of a significant 
relationship between the response and a factor that prevents introducing in the model a second factor 
which considered individually have a significant relationship with the response but which, being 
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correlated with another factor already introduced in the model, its additional contribution to the variation 
of the response is not significant. 
3. - The relationship between critical factor and critical response is determined and also the best 
combination of factors to produce the industrial batch is established. 
Based on the data in Table 6, it can be assumed deduced that only one factor does not significantly 
influence (probability level of 95%) in any of the responses studied; that is the “I” factor or relative 
humidity during cooling. The rest have a significant influence on one or more of the responses. 
Therefore any factor level within the range will be suitable for obtaining a correct product. 
Similarly, only one response is not significantly influenced by any of the factors studied that is impurity 
B. It can thus be concluded that it is probably due to the raw material (API). 
Also in table Table 6 it can be seen shows that the most important factors influencing the final 
specifications are those relating to the characteristics of the API: particle size, % retained in the 500 
micron sieve (both significantly influence in 4 responses) and water content API (influences significantly 
in 3 responses). These relationships are discussed below. 
4. DISCUSSION 
4.1. ANALYSIS OF THE MAIN FACTORS WITH SIGNIFICANT INFLUENCE ON THE PRODUCT 
SPECIFICATIONS 
4.1.1. STUDIED RESPONSE STUDIED: INTERNAL PHASE YIELD 
According to Table 6, only one factor (drying time) significantly influences this response. By increasing 
the drying time, the internal performance of the granulate increases. The specification of this response 
is 80-105%, and so between 10 and 15 minutes (design space) will be required for the specified 
performance and nearly at 100%. 
Logically this drying time will depend on the moisture during drying. In graph (Figure 4) the area is 
marked that ensures a correct product (work or control space). 
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4.1.2. STUDIED RESPONSE STUDIED: API CONTENT 
In this case the theoretical content is 12.5 mg and should be between 11.9-13.1 mg, Figure 5 shows 
the space studied and it can be observed that by working on the area to the right we will always obtain 
tablets within specifications and so we should preferably work in the area between 70 and 91 microns 
and between 0 and 0.4% retention. It can be seen from the graph that although these ranges are 
exceeded, the product is still correct, except when working with a very small particle size and the % 
retention is high, and so its design space could be 47-91 microns (API particle size) and from 0 to 0.7% 
(% retention of API). 
 
4.1.3. STUDIED RESPONSE STUDIED: RSD CONTENT IN API 
In this case we are interested in obtaining low percentages of (or) near-to-zero  variation, corresponding 
to the area (left of the graph, Figure 6), that is, the control interval would be to work between 2.1-2.35 L 
of amount of binder and between 0.1- 0.2% of API water content (area shown on the left side of Figure 
6), although the entire graph is within specifications, and so design space would be the entire area 
between 2.1 and 2.9 L of amount of binder and 0.1 to 0.2% of API water content. 
 
4.1.4. STUDIED RESPONSE STUDIED: PERCENTAGE DISSOLUTION AFTER 15 MINUTES 
Figure 7 shows that all batches meet the specifications (≥ 80%), with just the area on the left remaining 
without. Therefore, the work zone would be for the amount of binder of between 2.35 to 2.9 L, although 
as a working range it would be advisable to work between 2.35 and 2.7 L. For drying  moisture, we 
ensure dissolution provided we work below 0.73%. Clearly our concern is for both factors to be at their 
low level. See Figure 8 of the main effects, maximum dissolution levels are obtained when the factors 
are at their lowest level for both the amount of binder and for the moisture drying factor (left side of the 
line). For particle size factor, the best level would be the largest size, although the difference between 
the two levels is not very large (low gradient of the line). 
Page 15 of 34
URL: http://mc.manuscriptcentral.com/lpdt
































































 - 15 - 
 
4.1.5. STUDIED RESPONSE STUDIED: IMPURITY A 
In the case of impurity A (specification of <0.1%) only the particle size of the API appears as a 
significant factor. The whole graph would give a correct product (Figure 9). However to find the optimal 
point (lowest possible impurity) it is best for the API to have the lowest particle size as it will give the 
minimum impurity level. 
4.1.6. STUDIED RESPONSE STUDIED: IMPURITY B 
As mentioned, impurity B is not influenced by any studied preparation factor. It can be seen in the 
graph (Figure 10) that it does not vary; it must be an impurity that comes with the API and the 
preparation of the tablet does not influence the level. 
 
4.1.7. STUDIED RESPONSE STUDIED: IMPURITY C 
For impurity C three factors appear which have a significant influence: the % of particles retained > 500 
microns, consumption during kneading, and blending time. The specification also is <0.1%. In this case, 
the graphs (Figures 11, 12 and 13) only relate two factors at the same time, but it can be seen that all 
areas give a correct product, below 0.1%, and the maximum impurity obtained in the three figures is 
0.04%. To introduce the third factor it is worth consulting figure 14 in which the combination of factors 
and levels which give a higher level of impurity C is marked. 
Therefore it would be best to work at maximum consumption, maximum mixture time and maximum % 
retention. Regarding the control space it would be 6.6 to 6.8 Kw for kneading consumption and 0.3-1% 
for particles of 500 microns and 1162-1174 seconds blending time. 
 
4.1.8. STUDIED RESPONSE STUDIED: OTHER IMPURITIES 
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Regarding the other impurities response, the only significant factor was drying moisture. It can be seen 
in the graph (Figure 15) that when it is at a high level between 0.80% and 0.93%, minimum levels are 
reached, which is proposed as control space, and the entire area is design space. 
 
4.1.9. STUDIED RESPONSE STUDIED: TOTAL IMPURITIES 
The specification in this case is ≤ 0.5% and the two factors significantly influencing (Table 6) are API 
particle size and % of the particles retained > 500 microns. In this case the minimum levels are found 
when working with particle sizes of between 31–71 µm, as long as that the retained particles are 
between 0.6 and 1%, so that this will be the work or control space and the entire interval gives a level 
within specifications which will be the design space (figure 16). 
 
4.1.10. STUDIED RESPONSE STUDIED: MIXTURE CONTENT 
The theoretical specification in this case is 121.4 mg/g granulate or between 115.3-127.5 mg/g. It can 
be seen in Table 6 that the content will depend on the characteristics of the API (particle size and % 
particles greater than 500 microns) and the amount of binder. 
In the graph of two factors (Figure 17) the area is marked representing the control space for the API 
particle size which would be between 60 and 91 microns and % retention > 500 microns would be 
between 0 and 0.6%. 
To study the third factor another graph (Figure 18) has been devised in which it can be seen that the 
amount of binder at the level between 2.6 and 2.9 L for any level of % particles retained will give a 
product within specifications. 
As we are dealing with three factors, the design and control space is detailed in Table 7. 
 
4.1.11. STUDIED RESPONSE STUDIED: RSD BLEND CONTENT 
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In this case (Figure 19) it is clear that the area of interest is the right-hand side with the lowest RSD, 
and therefore it will be preferable to work between 0.16 and 0.2 % API water content at any blending 
time. The entire area is the design space since it meets specifications 
 
4.1.12. STUDIED RESPONSES STUDIED: BLEND WATER CONTENT 
In this case we require the granulate not to be excessively dry and so it must be in the upper clearer 
zone. The most influential factor is API moisture (at higher moisture of the API, higher moisture of the 
final mixture); in fact the entire area of the graph would meet the specifications (Fig. 20). However, as a 
control area it could be recommended with the drying moisture between 0.69 to 0.93% to obtain a 
granulate that is not excessively moist. 
 
4.2. SUMMARY OF FACTORS AND OPTIMAL LEVELS FOR THE QUALITY OF THE TABLET: 
CONTROL SPACE DURING MANUFACTURING 
The experimental design conducted gives optimal conditions that will depend on each response and 
sometimes they can be contrasted and so some recommendations of commitment should be 
established. Now, the established intervals are tabulated with the previous graphs (Figures 4-20) 
analyzing the data of Table 8 to ascertain what would be the final conditions of the design space. 
However, although there is a statistically significant relationship between impurities (impurity A and total 
impurities) and particle size of the API, technically it does not seem to be consistent, and it should be 
studied with supplier data to see if the different particle sizes of the API relate to process conditions or 
incidents, as detected by the statistical analysis performed. 
 
4.3. PROPOSED DESIGN SPACE 
The fourth and final step is to establish the design space for the compression process; the intervals are 
shown in the last row of Table 8. It can be seen that the intervals forming the design space are 
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narrower than the previous specifications, which does not affect the regulatory aspects of the product, 
since they are included. The advantage is that if you work within these ranges, the product will always 
be within specifications for the 8 responses studied and these are always around the theoretical 
specification, a clear improvement given that by reviewing the raw data of the 23 batches, variability 
was detected especially for specifications such as dissolution (average of 23 batches: 95.7%, 4.9% 
RSD, with the maximum average value obtained standing at 104% and the minimum at 87%), which 
means that variability would  decrease. 
 
5. CONCLUSIONS 
Process understanding is the major goal of a QbD program. A process is well understood when all the 
critical sources of variability are identified and explained; when variability is managed by the process, 
and when product quality attributes can be accurately and reliably predicted over the design space 
established for materials used, process parameters, manufacturing, environmental and other conditions 
(US FDA, 2004). The QbD principles provide a structured approach for gaining process knowledge and 
developing a robust manufacturing process. Based on process understanding a design space has been 
developed to consistently ensure tablet quality. However the application of the QbD principles for the 
existing products is very limited. In this case it has been applied successfully to the first stage of an 
industrial process for producing coated tablets. On the basis of process understanding, it has been 
demonstrated that the process can ensure correct tablet production and focus on the specifications 
(particularly on impurities and dissolution) by controlling the critical process variables. 
Risk analysis was successfully utilized to identify operating parameters for process characterization. So 
9 factors were examined in process characterization studies. Using the design of experiments (DoE), 
characterization studies were performed. Of all operating parameters characterized, 8 factors were 
identified as key operating parameters. Only one parameter was non-key or non-critical: relative 
humidity during cooling. 
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Finally, based on the results of small-scale studies, acceptable ranges were set for the characterized 
operating parameters to define the design space for the product. The approach presented here is not 
specific to the illustrated case study. The method can be extended to other pharmaceutical unit 
operations and processes that can be characterized at industrial scale. 
In the case of this study, it is determined that the incorporation of methodologies or hardware to 
improve the current process is not required. The process is robust and capable of obtaining a product 
that meets all the quality attributes recorded. 
 
As a result of the failure modes evaluated and after verification with production data, the most important 
and obvious conclusion that can be drawn is that the process is stable and the possible incorporation of 
improvements to mitigate the existing risks will have a minimal impact on to improving improve the 
current quality assurance, since it is very high for the present current process. 
Because of the great robustness of the API and of the manufacturing method under study, a priori any 
additional control plan to the existing ones can be ruled out since the variability of the process does not 
warrant any extra investment in the current process. 
In view of the information supplied by the factory and laboratory data it can be assumed deduced that 
the way of eliminating risks in this process involves a decrease in the severity of the failures and a 
reduction of unnecessary steps to reduce the number of risk stages (such as those responsible for 
increased degradation impurities, namely impurity C, which is directly affected by the API water content; 
the greater the moisture, the more impurity C). 
Finally, despite the limitations of applying the concept of QbD for existing products, it should be noted 
that the strategy implemented helps the "the improvement in life" of the product since additional data to 
industrial development data, when well studied, will help to go deeper into the process and its 
continuous improvement. Following this working line of process understanding, it could be interesting to 
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study the granulation process (from the point of view of the solid-liquid transitions). This could be a 
good starting point for further studies to improve the knowledge of the current process. 
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 Figure legends: 
Figure 1: Process Map 
Figure 2: Qualitative Risk Analysis (multivariable causes and effects relationship) for process and API 
Figure 3: Pareto analysis 
Figure 4: Surface contours of internal phase yield (Design space and control space) 
Figure 5: Surface contours of API content (Design space and control space) 
Figure 6: Surface contours of RSD final blend content (Design space and control space) 
Figure 7: Estimated response surface of dissolution (Design space and control space) 
Figure 8: Main effect chart for dissolution 
Figure 9: Surface contours of Impurity A 
Figure 10: Estimated response surface of  Impurity B  
Figure 11: Estimated response surface of  Impurity C (factors studied kneading consum & part>500 
µm). 
Figure 12: Estimated response surface of  Impurity C (factors studied  part>500 µm& blending time). 
Figure 13: Estimated response surface of  Impurity C (factors studied kneading consum & blending 
time) 
Figure 14: Cube graph of impurity C 
Figure 15: Estimated response surface of other impurities 
Figure 16: Estimated response surface of Total impurities 
Figure 17: Surface contours of blend content  
Figure 18: Estimated response surface of blend content 
Figure 19: Surface contours of RSD blend content  
Figure 20: Surface contours of blend water content 
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Table 1: Part A: Scales for the assessment of Severity, Occurrence and Detectability. Part B: 








10 Severe impact on quality. It generates OOS without possibility of expert report 
7 
Significant impact on the quality. It can generate OOS, no stability data available, it 
is possible an expert report 
3 Minor impact on quality. It can be OOS, stability data available 




1 Improbable or single event 
DETECTABILITY 
4 
Can not be 
detected 
Without manual control, failure detected as a "discovery" 
2 Usually detected 
Manual control, it is worked with statistical control or it’s 
detected at a later stage of the process 




10 7 3 1 
OCCURRENCE x 
DETECTABILITY 
16 160 112 48 16 
8 80 56 24 8 
4 40 28 12 4 
2 20 14 6 2 
1 10 7 3 1 
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Table 2: Classification of risk levels and actions planned 
 
 
Action Level Actions to take 
Level 3 
It’s unacceptable to keep the current process. You must to act on one 
(or more) of the parameters to mitigate the situation. 
Level 2 
It is necessary to evaluate the current process and act on any of the 
factors. It is established the action level at R.P.N. ≥ 16 
Level 1 
The current process risk is acceptable. It’s not priority to act on these 
failures. 
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Table 3: Risk analysis results obtained for all studied process steps. 
 









1.  INGREDIENT (API) Particle size 
Does not meet specification: 
dissolution profile, content and 
content uniformity 
10 2 1 20 
2.  INGREDIENT (API) Water content 
Does not meet specification: 
water content and stability 
7 1 1 7 
3.  INGREDIENT (API) Impurities content 
Does not meet specification: 
related substances  




Particle size  
Does not meet specification: 
dissolution profile  





Does not meet specification: 
water content and stability 
3 1 1 3 
6.  PRE-BLEND Blending time  
Does not meet specification: 
content and uniformity content 
10 1 1 10 
7.  PRE- BLEND Blending speed  
Does not meet specification: 
content and uniformity content 
10 1 1 10 
8.  PRE- BLEND 
Addition order of 
components 
Does not meet specification: 
content and uniformity content 
1 1 1 1 
9.  GRANULATION 
Binding liquid 
quantity 
Does not meet specification: 
dissolution profile, water content 
and stability 
10 2 2 40 
10.  GRANULATION 
Binding solution 
addition rate 
Does not meet specification: 
dissolution profile 
10 1 1 10 




Does not meet specification: 
dissolution profile 
10 2 1 20 
12.  MILL Rotation speed 
Does not meet specification: 
water content and stability 
3 1 1 3 
13.  MILL Product inlet 
Does not meet specification: 
water content and stability 





Does not meet specification: 
dissolution profile, related 
substances and stability 






Does not meet specification: 
dissolution profile, water content, 
related substances and stability 





Does not meet specification: 
dissolution profile, water content, 
related substances and stability 




Moisture at the 
end of drying 
Does not meet specification: 
related substances and water 
content 






Does not meet specification: 
related substances and water 
content 




Moisture at the 
end of cooling 
Does not meet specification: 
related substances and water 
content 
10 2 1 20 
20.  FINAL SIEVING Sieve size 
Does not meet specification: de 
dissolution profile, content and 
uniformity content 
10 1 1 10 
21.  FINAL SIEVING Product inlet 
Does not meet specification:  
content and uniformity content 
1 2 2 4 
22.  FINAL BLEND 
Addition order of 
components 
Does not meet specification: 
content and uniformity content 
1 1 1 1 
23.  FINAL BLEND Blending time  
Does not meet specification: 
content and uniformity content 
10 1 1 10 
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24.  FINAL BLEND Speed 
Does not meet specification: 
content and uniformity content 
10 1 1 10 
25.  ROOM CONDITIONS Pressure 
Cross contamination of 
contiguous rooms 
1 2 1 2 
26.  ROOM CONDITIONS Temperature 
Impact on drying conditions and 
time 
1 2 1 2 
27.  ROOM CONDITIONS Humidity 
Impact on drying conditions and 
time 
1 2 1 2 
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Table 4: Data available for the DOE analysis, potential process variables (factors to be studied for 





AVALAIBLE DATA FROM  
QUALITY CONTROL LABORATORY 
AVALAIBLE DATA FROM 
PRODUCTION 
(phase I). 
API FINAL BLEND FINISHED PRODUCT PROCESS DATA 
Particle size  
>500 µ (%) 
API Content (mg/g) Assay (mg/comp) Addition of binding liquid (L) 
Average particle 
size (µ) 
RSD (%) Dissolution test (%) 
Power consumption on 
endpoint kneading (Kw) 
Water Content (%) Water Content  (%) RSD (%) Drying time (min) 
   Related Substances (%) 
   Impurity A  
   Impurity B 
   Impurity C 
   Other Impurities  
   Total Impurities 
Drying Moisture (%) 
Cooling Moisture (%) 
Blending time (seconds) 
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Specification to meet 
Internal phase Yield 86.4 101.7 80-105% 







0.7 2.5 ≤4% 
Dissolution test 88 104 ≤80% 
Impurity A (tablet) 0 0.05 ≤ 0.1% 
Impurity B (tablet) 0 0.04 ≤ 0.1% 
Impurity C (tablet) 0 0.04 ≤ 0.1% 
Other impurities  
(tablet) 
0 0.05 ≤ 0.1% 
Total Impurities  
(tablet) 
0.03 0.1 ≤ 0.5% 
Final blend content 117.9 127.4 
121.4 mg/g 
115.3-127.5 mg/g 
RSD final blend 
content 
0.4 3.6 ≤4% 
Final blend water 
content 
0.7 1.5 ≤1.5% 
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Table 6: Significant relationships found between the studied factors and responses for the 
preparation of tablets. Numbers no underlined: factors that have a negative effect on the 
response (decrease) by increasing factor. Numbers in italics, bold and underlined those that have 
a positive effect on the response (increase) by increasing factor. The grey box means that there 
is no statistically significant relationship between factor and response (p<0.05). The numbers 
inside the grey boxes means that there is a relationship between factor and response but no 
statistically significant (p>0.05).  
 
 FACTORS 























        
A B C D E F G H I 
Internal phase 
Yield 
  0,0052       
API Content  0.0700  0.0084 0.0147     
Dissolution 0.0014   0.1460    0.0017  
RSD Content 0.0234     0.0328    
Imp. A    0.0288      
Imp. B     0.0926     
Imp. C  0.0079   0.0033 0.0716 0.0170   
Other Imp.     0.0613    0.0039  
Total Imp.  0.0900  0.0264 0.0295     
Blend content 0.0095   0.0069 0.0012     
RSD Blend 
content 
     0.0176    
Blend water 
content 
     0.0102  0.0016  
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Table 7: Combination of the three factors that provide an optimized response of the content of 
blend before compression. 
 
 Control or work space Design space 
Retained particles greater than 
500 microns (%) 
0-0.2 0-0.6 
API particle size (µm) 71-91 61-91 
Binding liquid quantity (L) 2.8-2.9 2.6-2.9 
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Table 8: Final ranges obtained for the process. In the last row of the table are highlighted 


































A B C D E F G H I 
Internal phase Yield   10-15       
API Content    47-91 0-0.7     
RSD Content 2.1 - 2.8     0.1-0.15    
Dissolution 2.35 - 2.8       0.53-0.73  
Imp. A    31-90      
Imp. B          
Imp. C  6 - 6.7   0 -1  1150.1170   
Other Imp.         0.53-0.93  
Total Imp.    31-91 0-1     
Blend content 2.6-2.8   61 -91 0-0.6     
RSD Blend content      0.1- 0.2    
Blend water content      0.1 -0.14  0.69-0.93  
Final 
recommendation 
2.6-2.8 6 - 6.7 10 -15 31 - 91 0 - 1 0.1-0.2 1150-1170 0.53-0.93 Whatever 
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